Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
BMRN Quote, Financials, Valuation and Earnings
Last price:
$59.94
Seasonality move
:
5.6%
Day range:
$59.81 - $61.24
52-week range:
$50.76 - $73.51
Dividend yield:
0%
P/E ratio:
22.54x
P/S ratio:
3.81x
P/B ratio:
1.91x
Volume:
1.2M
Avg. volume:
3.4M
1-year change:
-9.71%
Market cap:
$11.6B
Revenue:
$2.8B
EPS (TTM):
$2.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.34 | 11.37% | 43.52% | $89.74 |
|
ABBV
AbbVie, Inc.
|
$15.6B | $1.78 | 8.54% | 103.87% | $244.68 |
|
BMY
Bristol Myers Squibb Co.
|
$11.8B | $1.52 | -0.85% | 4631.67% | $55.09 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.49% | 33.42% | $132.38 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.84% | 39.23% | $110.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$60.16 | $89.74 | $11.6B | 22.54x | $0.00 | 0% | 3.81x |
|
ABBV
AbbVie, Inc.
|
$229.89 | $244.68 | $406.3B | 173.46x | $1.64 | 2.85% | 6.83x |
|
BMY
Bristol Myers Squibb Co.
|
$54.71 | $55.09 | $111.4B | 18.47x | $0.62 | 4.53% | 2.32x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
GILD
Gilead Sciences, Inc.
|
$125.67 | $132.38 | $155.9B | 19.46x | $0.79 | 2.52% | 5.44x |
|
MRK
Merck & Co., Inc.
|
$106.45 | $110.04 | $264.2B | 14.08x | $0.85 | 3.08% | 4.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
ABBV
AbbVie, Inc.
|
104% | -0.046 | 16.8% | 0.47x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.073 | 56.92% | 0.94x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
ABBV
AbbVie, Inc.
|
$10.4B | $4.6B | 3.31% | 144.3% | 29.03% | $6.6B |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
BioMarin Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns BMRN or ABBV?
AbbVie, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 1.13%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B ABBVAbbVie, Inc.66.12% $0.10 $66.1B -
What do Analysts Say About BMRN or ABBV?
BioMarin Pharmaceutical, Inc. has a consensus price target of $89.74, signalling upside risk potential of 49.17%. On the other hand AbbVie, Inc. has an analysts' consensus of $244.68 which suggests that it could grow by 6.43%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than AbbVie, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.13 7 0 ABBVAbbVie, Inc.14 8 0 -
Is BMRN or ABBV More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.24%.
-
Which is a Better Dividend Stock BMRN or ABBV?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $1.64 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 263.15% of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or ABBV?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than AbbVie, Inc. quarterly revenues of $15.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than AbbVie, Inc.'s net income of $178M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 22.54x while AbbVie, Inc.'s PE ratio is 173.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.81x versus 6.83x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M ABBVAbbVie, Inc.6.83x 173.46x $15.8B $178M
-
Which has Higher Returns BMRN or BMY?
Bristol Myers Squibb Co. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 17.96%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About BMRN or BMY?
BioMarin Pharmaceutical, Inc. has a consensus price target of $89.74, signalling upside risk potential of 49.17%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.69%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.13 7 0 BMYBristol Myers Squibb Co.4 18 1 -
Is BMRN or BMY More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.
-
Which is a Better Dividend Stock BMRN or BMY?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.53% to investors and pays a quarterly dividend of $0.62 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMRN or BMY?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 22.54x while Bristol Myers Squibb Co.'s PE ratio is 18.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.81x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M BMYBristol Myers Squibb Co.2.32x 18.47x $12.2B $2.2B
-
Which has Higher Returns BMRN or FOLD?
Amicus Therapeutics, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 10.24%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About BMRN or FOLD?
BioMarin Pharmaceutical, Inc. has a consensus price target of $89.74, signalling upside risk potential of 49.17%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.13 7 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is BMRN or FOLD More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock BMRN or FOLD?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or FOLD?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 22.54x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.81x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns BMRN or GILD?
Gilead Sciences, Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 39.21%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a consensus price target of $89.74, signalling upside risk potential of 49.17%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.34%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.13 7 0 GILDGilead Sciences, Inc.16 8 0 -
Is BMRN or GILD More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock BMRN or GILD?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios BMRN or GILD?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 22.54x while Gilead Sciences, Inc.'s PE ratio is 19.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.81x versus 5.44x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M GILDGilead Sciences, Inc.5.44x 19.46x $7.8B $3.1B
-
Which has Higher Returns BMRN or MRK?
Merck & Co., Inc. has a net margin of -3.91% compared to BioMarin Pharmaceutical, Inc.'s net margin of 33.68%. BioMarin Pharmaceutical, Inc.'s return on equity of 8.99% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About BMRN or MRK?
BioMarin Pharmaceutical, Inc. has a consensus price target of $89.74, signalling upside risk potential of 49.17%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Merck & Co., Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings BMRNBioMarin Pharmaceutical, Inc.13 7 0 MRKMerck & Co., Inc.15 12 0 -
Is BMRN or MRK More Risky?
BioMarin Pharmaceutical, Inc. has a beta of 0.299, which suggesting that the stock is 70.071% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock BMRN or MRK?
BioMarin Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. BioMarin Pharmaceutical, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BMRN or MRK?
BioMarin Pharmaceutical, Inc. quarterly revenues are $786.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. BioMarin Pharmaceutical, Inc.'s net income of -$30.7M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, BioMarin Pharmaceutical, Inc.'s price-to-earnings ratio is 22.54x while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioMarin Pharmaceutical, Inc. is 3.81x versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M MRKMerck & Co., Inc.4.20x 14.08x $17.2B $5.8B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
